Lv5
950 积分 2023-08-30 加入
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
1天前
待确认
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
2天前
已完结
The evolving landscape of obesity pharmacotherapy
3天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
3天前
已完结
The story of amylin: from physiology to therapy
8天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
8天前
已完结
Calcitonin gene-related peptide (CGRP) and its role in hypertension
9天前
已完结
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
10天前
已完结
Amylin takes another shot at the obesity prize
10天前
已完结
RAMP1 and RAMP3 Differentially Control Amylin’s Effects on Food Intake, Glucose and Energy Balance in Male and Female Mice
11天前
已完结
皖公网安备34019202002308
